Anti-tumor activity of selinexor in combination with antineoplastic agents in chronic lymphocytic leukemia

Despite recent relevant therapeutic progresses, chronic lymphocytic leukemia (CLL) remains an incurable disease. Selinexor, an oral inhibitor of the nuclear export protein XPO1, is active as single agent in different hematologic malignancies, including CLL. The purpose of this study was to evaluate...

Descripción completa

Detalles Bibliográficos
Autores principales: Vitale, Candida, Griggio, Valentina, Todaro, Maria, Riganti, Chiara, Jones, Rebecca, Boccellato, Elia, Perutelli, Francesca, Arruga, Francesca, Vaisitti, Tiziana, Efremov, Dimitar G., Deaglio, Silvia, Landesman, Yosef, Bruno, Benedetto, Coscia, Marta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10560255/
https://www.ncbi.nlm.nih.gov/pubmed/37805613
http://dx.doi.org/10.1038/s41598-023-44039-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10560255/
https://www.ncbi.nlm.nih.gov/pubmed/37805613
http://dx.doi.org/10.1038/s41598-023-44039-0

Ejemplares similares